Parkinson's disease (PD) is the second most common neurodegenerative disease. The
characteristic feature of PD is the progressive degeneration of the dopaminergic (DAergic) …

In 1967, L-dopa was introduced as part of the pharmacological therapy of Parkinson's
disease (PD) and, in spite of extensive research, no additional effective drugs have been …

The positive effect of levodopa in the treatment of Parkinson's disease, although it is limited
in time and has severe side effects, has encouraged the scientific community to look for new …

Investigations of the effect of antioxidants on idiopathic Parkinson's disease have been
unsuccessful because the preclinical models used to propose these clinical studies do not …

Dopamine's ability to oxidize to aminochrome explains why this molecule may be a
neurotoxic compound that induces toxicity in both cell lines and animal models …

Parkinson's disease (PD) is a neurodegenerative disorder that progresses over time and is
characterized by preferential reduction of dopaminergic neurons in the substantia nigra …

Neuromelanin (NM) accumulates in catecholamine long-lived brain neurons that are lost in
neurodegenerative diseases. NM is a complex substance made of melanic, peptide and …

Causes of dopaminergic neuronal loss in Parkinson's disease (PD) are subject of
investigation and the common use of models of acute neurodegeneration induced by …

Glutathione is an important antioxidant that plays a crucial role in the cellular protection
against oxidative stress and detoxification of electrophilic mutagens, and carcinogens …

The identity of what triggers the loss of dopaminergic neurons containing neuromelanin in
Parkinson's disease (PD) is still unknown. Fifty years since its introduction in PD therapy, L …